- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00745225
Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients (PPAR)
October 1, 2021 updated by: Dr. Angela Yee-Moon Wang, The University of Hong Kong
Targeting Peroxisome Proliferator-Activated Receptor-Gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients? (PROOF Trial)
To study whether peroxisome proliferator-activated receptor-gamma activation in peritoneal dialysis patients will reduce inflammation, atherosclerosis, calcification and improve survival of peritoneal dialysis patients
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Peritoneal dialysis patients are at increased risk of cardiovascular morbidity and mortality and are related to the presence of accelerated atherosclerosis.
Other than the traditional cardiovascular risk factors, there is increasing evidence that inflammation is associated with the development of atherosclerosis and cardiovascular events in both the general and dialysis population.
C-reactive protein is predictive of higher all-cause mortality and cardiovascular mortality, independent of other cardiovascular risk factors and atherosclerotic vascular disease.
As a considerable proportion of peritoneal dialysis patients showed elevated C-reactive protein, it raises an important question as to whether lowering C-reactive protein will have any cardiovascular and survival benefit in these patients.
On the other hand, insulin resistance with associated hyperinsulinemia is frequently observed in chronic renal failure and dialysis patients.
Although the exact mechanism of insulin resistance needs further evaluation, studies indicated that insulin resistance is an important cardiovascular risk factor and outcome predictor in the general and dialysis population.
Moreover, recent evidence indicates an association between chronic inflammation and insulin resistance although the exact interrelationship remains unclear.
The peroxisome proliferator-activated receptor-gamma (PPAR-g) is a member of the nuclear receptor family of ligand-dependent transcription factors.
PPAR-g is highly expressed in adipose tissue and clinical study has confirmed efficacy of the specific ligands for PPAR-gamma, namely thiazolidinediones (TZD), in improving insulin sensitivity.
Recent experimental and clinical studies demonstrated that TZD has anti-inflammatory and anti-atherosclerotic properties other than insulin sensitizing effect in type 2 diabetics.
We hypothesize that modulation of the PPAR-g activity may be a novel therapeutic strategy for reducing inflammation and improving insulin sensitivity and may retard the progression of atherosclerosis and possibly reduce mortality of our peritoneal dialysis patients.
Study Type
Interventional
Enrollment (Actual)
160
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hong Kong, Hong Kong, 0000
- Queen Mary Hospital, Tung Wah Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Both prevalent patients or patients newly started on continuous peritoneal dialysis, with or without diabetes mellitus will be considered eligible for study entry.
- For patients newly started on chronic peritoneal dialysis, they will be suitable for recruitment into the study after one month on peritoneal dialysis.
- Patients who provide informed consent for the study
Exclusion Criteria:
- Patients with underlying active malignancy
- Patients with chronic liver disease or liver cirrhosis
- Patients with active infections
- Patients with other chronic active inflammatory disease such as systemic lupus erythematosus, rheumatoid arthritis
- Patients who refuse study participation
- Patients with underlying congenital heart disease or rheumatic heart disease
- Patients with poor general condition
- Patients with plans for living related kidney transplant within 2 years
- Female patients with pregnancy
- Patients with history of recurrent hypoglycemia
- Patients with Class III and IV congestive heart failure
- Patients already receiving glitazones treatment at the screening visit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active intervention arm
Peroxisome proliferator activator receptor gamma treatment, Pioglitazone
|
pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks
Other Names:
|
Placebo Comparator: placebo pill
placebo comparator
|
1 capsule daily, 96 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in carotid intima-media thickness
Time Frame: over 48 weeks
|
Change in carotid intima-media thickness
|
over 48 weeks
|
change in flow mediated dilatation (marker of endothelial function)
Time Frame: over 48 weeks
|
change in flow mediated dilatation (marker of endothelial function)
|
over 48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in aortic pulse wave velocity
Time Frame: over 96 weeks
|
change in aortic pulse wave velocity
|
over 96 weeks
|
change in augmentation index-heart rate adjusted
Time Frame: over 96 weeks
|
change in augmentation index-heart rate adjusted
|
over 96 weeks
|
change in nitroglycerin-mediated dilatation
Time Frame: over 48 weeks
|
change in nitroglycerin-mediated dilatation
|
over 48 weeks
|
change in coronary artery calcium score
Time Frame: over 96 weeks
|
change in coronary artery calcium score
|
over 96 weeks
|
change in heart valves calcium score
Time Frame: over 96 weeks
|
change in heart valves calcium score
|
over 96 weeks
|
change in carotid artery calcium score
Time Frame: over 96 weeks
|
change in carotid artery calcium score
|
over 96 weeks
|
change in abdominal visceral fat
Time Frame: over 96 weeks
|
change in abdominal visceral fat
|
over 96 weeks
|
change in subcutaneous fat
Time Frame: over 96 weeks
|
change in subcutaneous fat
|
over 96 weeks
|
change in blood pressure
Time Frame: over 96 weeks
|
change in blood pressure
|
over 96 weeks
|
change in C-reactive protein
Time Frame: over 96 weeks
|
change in C-reactive protein
|
over 96 weeks
|
change in residual kidney function
Time Frame: over 96 weeks
|
change in residual kidney function
|
over 96 weeks
|
change in HOMA index (among those not on insulin)
Time Frame: over 96 weeks
|
Change in insulin resistance index
|
over 96 weeks
|
change in D/P creatinine ratio
Time Frame: over 96 weeks
|
Change in peritoneal solute transport parameter
|
over 96 weeks
|
change in peritoneal ultrafiltration with 2.5% during PET
Time Frame: over 96 weeks
|
Change in peritoneal ultrafiltration volume
|
over 96 weeks
|
change in handgrip strength
Time Frame: over 96 weeks
|
change in handgrip strength
|
over 96 weeks
|
Change in cardiac biomarkers
Time Frame: over 96 weeks
|
change in cardiac biomarkers
|
over 96 weeks
|
change in insulin dose (among those on insulin)
Time Frame: over 96 weeks
|
change in insulin dose
|
over 96 weeks
|
change in endothelial progenitor cells
Time Frame: over 96 weeks
|
change in endothelial progenitor cells
|
over 96 weeks
|
change in central systolic blood pressure
Time Frame: over 96 weeks
|
change in central systolic blood pressure
|
over 96 weeks
|
Change in central diastolic blood pressure
Time Frame: over 96 weeks
|
change in central diastolic blood pressure
|
over 96 weeks
|
change in glycemic control (fasting glucose, and glycosylated hemoglobin)
Time Frame: over 96 weeks
|
change in glycemic control
|
over 96 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival
Time Frame: over 96 weeks
|
Hard outcome
|
over 96 weeks
|
major adverse cardiovascular event-free survival
Time Frame: over 96 weeks
|
hard outcome
|
over 96 weeks
|
Fluid overload/heart failure event-free survival
Time Frame: over 96 weeks
|
hard outcome
|
over 96 weeks
|
myocardial infarction event-free survival
Time Frame: over 96 weeks
|
hard outcome
|
over 96 weeks
|
3 point major adverse cardiovascular event-free survival
Time Frame: over 96 weeks
|
Hard outcome
|
over 96 weeks
|
4 point major adverse cardiovascular event-free survival
Time Frame: over 96 weeks
|
Hard outcome
|
over 96 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Angela YM Wang, MD, PhD, FRCP, University of Hong Kong, Queen Mary Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2006
Primary Completion (Actual)
October 1, 2014
Study Completion (Actual)
December 1, 2014
Study Registration Dates
First Submitted
September 1, 2008
First Submitted That Met QC Criteria
September 2, 2008
First Posted (Estimate)
September 3, 2008
Study Record Updates
Last Update Posted (Actual)
October 8, 2021
Last Update Submitted That Met QC Criteria
October 1, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A111-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End-stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
-
Guangdong Provincial Hospital of Traditional Chinese...Ministry of Science and Technology of the People´s Republic of ChinaUnknown
-
University of California, San FranciscoCompletedEnd-stage Renal DiseaseUnited States
-
Mark A. LumleyHenry Ford Health SystemCompleted
Clinical Trials on Pioglitazone
-
Dong-A ST Co., Ltd.CompletedType 2 DiabetesKorea, Republic of
-
Solvay PharmaceuticalsCompletedType 2 Diabetes MellitusUnited Kingdom
-
Emory UniversityCompletedDiabetic Ketoacidosis | Ketosis Prone Diabetes | Severe HyperglycemiaUnited States
-
University at BuffaloTakeda Pharmaceuticals North America, Inc.Completed
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceNot yet recruitingANCA Associated Vasculitis | Rapidly Progressive Glomerulonephritis | Crescentic Glomerulonephritis
-
National Cancer Institute (NCI)CompletedHead and Neck Cancer | Oral LeukoplakiaUnited States
-
University of Campinas, BrazilRecruitingMyocardial Reperfusion InjuryBrazil
-
West Virginia UniversityRecruitingBreast Cancer | Muscle FatigueUnited States
-
University of Texas Southwestern Medical CenterNational Institutes of Health (NIH)Completed
-
University of Texas Southwestern Medical CenterRecruitingNephrolithiasis, Uric AcidUnited States